280 related articles for article (PubMed ID: 19258444)
1. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
2. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
[TBL] [Abstract][Full Text] [Related]
3. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.
Yu H; Steeghs N; Kloth JS; de Wit D; van Hasselt JG; van Erp NP; Beijnen JH; Schellens JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2015 May; 79(5):809-19. PubMed ID: 25393890
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
[TBL] [Abstract][Full Text] [Related]
5. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
de Wit D; van Erp NP; Khosravan R; Wiltshire R; Allred R; Demetri GD; Guchelaar HJ; Gelderblom H
BMC Cancer; 2014 Aug; 14():575. PubMed ID: 25102852
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Khosravan R; Motzer RJ; Fumagalli E; Rini BI
Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
10. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
11. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
[TBL] [Abstract][Full Text] [Related]
12. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Mizuno T; Fukudo M; Fukuda T; Terada T; Dong M; Kamba T; Yamasaki T; Ogawa O; Katsura T; Inui K; Vinks AA; Matsubara K
Ther Drug Monit; 2014 Jun; 36(3):310-6. PubMed ID: 24825438
[TBL] [Abstract][Full Text] [Related]
13. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.
Diekstra MH; Klümpen HJ; Lolkema MP; Yu H; Kloth JS; Gelderblom H; van Schaik RH; Gurney H; Swen JJ; Huitema AD; Steeghs N; Mathijssen RH
Clin Pharmacol Ther; 2014 Jul; 96(1):81-9. PubMed ID: 24566734
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
Yu Y; DuBois SG; Wetmore C; Khosravan R
AAPS J; 2020 Jan; 22(2):31. PubMed ID: 31975150
[TBL] [Abstract][Full Text] [Related]
15. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Bello CL; Sherman L; Zhou J; Verkh L; Smeraglia J; Mount J; Klamerus KJ
Anticancer Drugs; 2006 Mar; 17(3):353-8. PubMed ID: 16520665
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
Lindauer A; Di Gion P; Kanefendt F; Tomalik-Scharte D; Kinzig M; Rodamer M; Dodos F; Sörgel F; Fuhr U; Jaehde U
Clin Pharmacol Ther; 2010 May; 87(5):601-8. PubMed ID: 20376000
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
19. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]